International Journal of Biomedicine. 2020;10(1):20-23.
Originally published March 15, 2020
Atrial fibrillation (AF) is one of the most common arrhythmias encountered in clinical practice. It has been found that the presence of chronic heart failure increases the risk of AF by 5 times. Furthermore, with an increase in the severity of symptoms of heart failure, the incidence and severity of AF increases.
To date, markers of AF progression are not clearly defined. In this regard, it is relevant and reasonable to identify such markers in patients with heart failure (HF).
The aim of this research was to study the prognostic value of the 6-minute walk test (6MWT), NT-proBNP level, and left ventricular diastolic dysfunction (LVDD) for AF progression in patients with CHF. The study involved 96 participants with stable Class II and III CHF (the NYHA Functional Classification), who were included in the regional registry of CHF patients in September-November 2014. The data obtained showed that in patients with CHF, an increase in the level of Nt-proBNP, impaired myocardial relaxation, and a decrease in 6MWT distance may serve as predictors of AF progression with the transition of arrhythmias to stable forms.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.; ESC Scientific Document Group.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210.
- Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014 Apr 25;114(9):1483-99. doi:10.1161/CIRCRESAHA.114.302226.
- Tokmachev RE, Mukhortova MS, Budnevsky AV, Tokmachev EV, Ovsyannikov ES. Comorbidity of chronic heart failure and chronic obstructive pulmonary disease: features of pathogenesis, clinic and diagnosis. Cardiovascular Therapy and Prevention. 2018;17(6): 62-68. [Article in Russian].
- Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920-5.
- Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-9. doi: 10.1016/j.jacc.2007.09.064.
- Drobysheva ES, Tokmachev RE, Budnevsky AV, Kravchenko AYa. Predictive value of markers of cardiac cachexia in chronic heart failure. Cardiovascular Therapy and Prevention. 2016;15(4):80-83. [Article in Russian].
- Tokmachev RE, Budnevsky AV, Kravchenko AY. Ter Arkh. 2016;88(9):106-110. doi: 10.17116/terarkh2016889106-110. [The role of inflammation in the pathogenesis of chronic heart failure]. [Article in Russian].
- Budnevsky AV, Shurupova AD, Kravchenko AY, Tokmachev RE. Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure. Ter Arkh. 2019 Mar 30;91(3):36-41. doi: 10.26442/00403660.2019.03.000111.
- Tokmachev RE, Maksimov AV, Budnevsky AV, Batishcheva GA, Ovsyannikov ES, Kravchenko AYa, Kurgalin SD. A device for cardiorespiratory analysis and a method for evaluating a cardiorespiratory state. Patent for invention RUS No. 2637917. Application No. 2016148274 dated December 9, 2016. Publ. 12/07/2017.
- Tokmachev RE, Budnevsky AV, Kravchenko AYa. The possibility of non-pharmacological methods in increasing clinical efficiency of treating patients with chronic heart failure and metabolic syndrome. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2017;8(6):832-839.
- Shiryaev OYu, Yankovskaya VL, Budnevsky AV, Ovsyannikov ES. Psychosomatic aspects of congestive heart failure. International Journal of Biomedicine. 2017;7(3):248-250.
- Murakami N, Tanno M, Kokubu N, Nishida J, Nagano N, Ohnishi H, et al. Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data.Open Heart. 2017;4(1):e000573. doi: 10.1136/openhrt-2016-000573.
Received December 31, 2019.
Accepted January 22, 2020.
©2020 International Medical Research and Development Corporation.